相关实验视频
Updated: Jul 13, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
血管酶抑制剂:心血管疾病的新疗法概念?
R Corti1, J C Burnett, J L Rouleau
1CardioVascular Center, Cardiology, University Hospital Zurich, Switzerland. cardiotfl@gmx.ch
Circulation
|October 10, 2001
概括
血管酶抑制剂,通过阻断ACE和中性内酶 (NEP),为心血管疾病提供了一个有前途的新疗法. 这种双重抑制增强了有益的和素,降低了血压,改善了血管功能.
科学领域:
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管系统依赖于血液动力学和神经性调节来维持平衡.
- 神经幽默系统的失调有助于心血管疾病,如高血压和心力衰竭.
- 中性内皮酶 (NEP) 降解尿素,素和上腺素,这些对血管健康至关重要.
研究的目的:
- 探索抑制心血管疾病中中性内酶 (NEP) 的治疗潜力.
- 评估ACE和NEP的联合抑制作为一种新的治疗策略.
主要方法:
- 研究中性内皮酶 (NEP) 的酶活性和基质特异性.
- 研究了NEP抑制对尿素,素和上腺素水平的影响.
- 评估了ACE和NEP联合抑制对血管收缩,血管扩张和血压的影响.
主要成果:
- 抑制NEP会增加尿素 (ANP,BNP,CNP),布拉迪基宁和上腺素的水平.
- 联合抑制ACE和NEP可以降低血管收缩并增强血管扩张.
- 这种双重抑制改善了/水平衡,降低了周围血管抵抗力,降低了血压.
结论:
- 联合抑制ACE和中性内酶 (NEP) 是心血管疾病的新疗法.
- 血管酶抑制剂通过调节多个神经道系统,在治疗高血压,动脉样硬化和心力衰竭方面表现有前途.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

